Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prediction of the potential biological activity of novel spiropyrazolo[3,4-b]pyridines and spiropyrazolo[3,4-b]pyridine-5,5'-pyrimidines by a ligand-protein inverse-docking approach.

Journal of molecular graphics & modelling·2020

Same author

Faecal contamination in public pools in Barcelona province: Cryptosporidium spp. and bacterial indicators.

Journal of water and health·2018

Same author

Could stress magnetic resonance imaging be useful in patients with a low probability of ischemic heart disease?

Radiologia·2018

Same author

[Patients with vulnerable coronary plaques have higher serum metalloproteinase-1 levels].

Anales del sistema sanitario de Navarra·2017

Same author

Structure and interaction with lipid membrane models of Semliki Forest virus fusion peptide.

Biochimica et biophysica acta·2016

Same author

Denitrification in a hypersaline lake-aquifer system (Pétrola Basin, Central Spain): the role of recent organic matter and Cretaceous organic rich sediments.

The Science of the total environment·2014

Search research articles

Related Experiment Video

Updated: Jul 9, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

[Heart failure. Current pharmacologic treatment].

I Coma-Canella¹, S Castaño, E Nasarre

¹Departamento de Cardiologia y Cirugia Cardiovascular, Clínica Universitaria, Facultad de Medicina, Universidad de Navarra, Pamplona. icoma@unav.es

Revista De Medicina De La Universidad De Navarra

|January 13, 2006

Summary

This summary is machine-generated.

Effective heart failure (HF) management combines multiple drug classes to improve symptoms and reduce mortality. Adding angiotensin-converting enzyme inhibitors, beta-blockers, and aldosterone antagonists significantly lowers mortality rates in HF patients.

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Related Experiment Videos

Last Updated: Jul 9, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Area of Science:

Cardiology
Pharmacology

Context:

Heart failure (HF) treatment has evolved significantly, focusing on symptom improvement and preventing disease progression.
Current therapeutic strategies aim to prevent the transition from asymptomatic systolic dysfunction to symptomatic HF, mitigate cardiac remodeling and renal dysfunction, and reduce overall mortality.

Purpose:

To review the current pharmacological approaches for heart failure management.
To highlight the additive benefits of combining different drug classes in HF treatment.
To discuss the role of specific drug families, including newer agents like Levosimendan for acute HF.

Summary:

Key drug classes for HF include cardiac glycosides, diuretics, ACE inhibitors (ACEI), beta-blockers (BB), angiotensin-II receptor blockers (ARB), and aldosterone receptor antagonists.
Combination therapy with ACEI, BB, and aldosterone antagonists demonstrates additive benefits, progressively reducing two-year mortality from 34% to 10% in mild to moderate HF.
While new positive inotropic drugs have not been approved for chronic HF due to increased mortality, Levosimendan shows promise in acute settings.

Impact:

Optimized drug combinations can significantly improve patient prognosis and reduce mortality in heart failure.
Understanding the additive effects of various drug classes allows for tailored treatment strategies to manage HF effectively.
The review underscores the importance of evidence-based pharmacological interventions in managing the complexities of heart failure.